p1images-istockphoto-com-money-
p1images / iStockphoto.com
29 November 2018Biotechnology

NHS to save £300m in biosimilar adalimumab deals

The National Health Service (NHS) England is set to make record-breaking savings after negotiating deals with five manufacturers of low-cost biosimilar versions of the NHS's most expensive drug.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
3 December 2018   AbbVie has granted Pfizer a non-exclusive global licence to its Humira IP, as announced on Friday, November 30.
Big Pharma
3 May 2019   The National Health Service, the UK’s government-run health system, has partnered with Gilead Sciences, Merck Sharp and Dohme and AbbVie to help eliminate hepatitis C in England.

More on this story

Americas
3 December 2018   AbbVie has granted Pfizer a non-exclusive global licence to its Humira IP, as announced on Friday, November 30.
Big Pharma
3 May 2019   The National Health Service, the UK’s government-run health system, has partnered with Gilead Sciences, Merck Sharp and Dohme and AbbVie to help eliminate hepatitis C in England.

More on this story

Americas
3 December 2018   AbbVie has granted Pfizer a non-exclusive global licence to its Humira IP, as announced on Friday, November 30.
Big Pharma
3 May 2019   The National Health Service, the UK’s government-run health system, has partnered with Gilead Sciences, Merck Sharp and Dohme and AbbVie to help eliminate hepatitis C in England.